
Capital intelligence at the intersection of women's wealth and women's health. Built for allocators navigating the Great Wealth Transfer.
| Platform | Pricing | Freemium | Publishes | Twice weekly | |
|---|---|---|---|---|---|
| Issues | 171 | Founded | 3 years ago | Last Issue | 8 days ago |
| Active | |||||

UCB’s acquisition of Candid Therapeutics is being framed as a next-generation immunology platform deal. But beneath the immune-reset narrative lies a commercial reality few investors are discussing.
📕Special note: My book The Billion Doll...
A few years ago, I sat in a doctor’s office and that experience marked the beginning of my journey into women’s health investing. Three years ago, I started writing what I thought was a report. It became a book about the gaps and opportunit...
The first non-hormonal menopause drug launched in 2023. Two and a half years later, the commercial case has not arrived. Bayer launched its competitor anyway. Here is what that says.
📕Special note: My book The Billion Dollar Blindspot is...
A few years ago, I sat in a doctor’s office and that experience marked the beginning of my journey into women’s health investing. Three years ago, I started writing what I thought was a report. It became a book about the gaps and opportunit...
The largest overseas acquisition in Indian pharmaceutical history transferred the world's biggest dedicated women's health portfolio to a biosimilar manufacturer. Here's what that means for allocators
📕Special note: My book The Billion Do...
Subscribers, engagement, traffic and sponsorship for The Billion Dollar Blindspot.
| Subscribers | Engagement | 78 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
The writers behind this newsletter.
Author of The Billion Dollar Blindspot. Capital intelligence for women's health investing. 20+ years in institutional capital. Zürich & London.
I'm an award-winning journalist with 30 years of experience covering science, health and wellness, and I cover all angles of the perimenopause, menopause and the midlife heroine's journey.
You can find recent issues that have been published by The Billion Dollar Blindspot on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
To see how many people subscribe to The Billion Dollar Blindspot, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
Newsletter advertising can be extremely effective when it's done right. Before you pitch The Billion Dollar Blindspot as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact The Billion Dollar Blindspot using the contact information provided and ask for a copy of their media kit.
Scroll up to where it says Related Newsletters to see other publications like The Billion Dollar Blindspot. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.